Ver Investigador - - Prisma - Unidad de Bibliometría

Francisco Javier Salvador Bofill

Investiga en

Tipo Año Título Fuente
Artículo2024 A Cross-Sectional Validation Study of Camry EH101 versus JAMAR Plus Handheld Dynamometers in Colorectal Cancer Patients and Their Correlations with Bioelectrical Impedance and Nutritional Status NUTRIENTS
Artículo2023 Abemaciclib, Palbociclib, and Ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Artículo2023 Evaluation of nutritional interventions in the care plan for cancer patients: the NOA project NUTRIENTS
Revisión2023 Targeting the tumor microenvironment in breast cancer: prognostic and predictive significance and therapeutic opportunities INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Artículo2022 Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: results from the Spanish sub-population of the phase 3b CompLEEment-1 trial Breast
Artículo2021 Análisis de las intervenciones nutricionales en el proceso asistencial del paciente oncológico en Andalucía: el proyecto NOA NUTRICION HOSPITALARIA
Artículo2020 Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01) JOURNAL OF CLINICAL ONCOLOGY
Artículo2019 Clinical impact of an educational antimicrobial stewardship program associated with infectious diseases consultation targeting patients with cancer: results of a 9-year quasi-experimental study with an interrupted time-series analysis JOURNAL OF INFECTION
Revisión2019 Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer CELLULAR ONCOLOGY
Corrección2018 Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice (vol 20, pg 862, 2018) CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2018 Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2017 Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2017 Defining the optimal sequence for the systemic treatment of metastatic breast cancer CLINICAL & TRANSLATIONAL ONCOLOGY
Revisión2017 Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions CLINICAL & TRANSLATIONAL ONCOLOGY
Corrección2017 Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions (vol 19, pg 341, 2017) CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2015 Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2014 362P ASSESSMENT OF TREATMENT RESPONSE WITH FULVESTRANT (F) 500 MG IN STANDARD CLINICAL PRACTICE THROUGH A RETROSPECTIVE STUDY: NCT01509625 ANNALS OF ONCOLOGY
Artículo2014 Bone turnover markers as predictive indicators of outcome in patients with breast and bone metastases treates with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study). BONE
Resumen congreso2013 Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625 JOURNAL OF CLINICAL ONCOLOGY
Ponencia2013 Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study JOURNAL OF CLINICAL ONCOLOGY
Artículo2012 Functions and workload of medical oncologists in Spain CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2012 Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2011 Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy Breast Cancer Research
Artículo2011 Role of the Intracellular pH in the Metabolic Switch between Oxidative Phosphorylation and AerobicGlycolysis - Relevance to Cancer WebmedCentral.com
Ponencia2010 CHRONOLOGY OF THE ARTERIAL HYPERTENSION ASSOCIATED WITH GROWTH FACTOR RECEPTOR INHIBITING TREATMENTS DERIVED FROM VASCULAR ENDOTHELIUM IN PATIENTS WITH CANCER JOURNAL OF HYPERTENSION
Ponencia2010 Chronology of the arterial hypertension associated with inhibiting treatments of vascular endothelium growth factor receptor in patients with cancer JOURNAL OF CLINICAL ONCOLOGY
Letter2010 The dark side of curcumin INTERNATIONAL JOURNAL OF CANCER
Artículo2010 Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM) ANNALS OF ONCOLOGY
Ponencia2009 PRIMARY BREAST SARCOMA: CLINICAL AND RETROSPECTIVE ANALYSIS OF CASES FROM JEREZ GENERAL HOSPITAL, SPAIN JOURNAL OF CLINICAL ONCOLOGY
Artículo2008 A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer CLINICAL & TRANSLATIONAL ONCOLOGY
Ponencia2008 Multicenter study of weekly trastuzumab, paclitaxel and carboplatin followed by a week of rest every 28 days in patients with HER2+metastatic breast cancer - incidence of central nervous system metastases European Journal Of Cancer. Supplement
Ponencia2008 Multicenter study of weekly trastuzumab, paclitaxel, and carboplatin followed by a week of rest every 28 days in patients with HER2+ metastatic breast cancer JOURNAL OF CLINICAL ONCOLOGY
Artículo2008 Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+metastatic breast cancer CANCER CHEMOTHERAPY AND PHARMACOLOGY
Ponencia2007 MULTICENTER STUDY OF WEEKLY TRASTUZUMAB, PACLITAXEL AND CARBOPLATIN FOLLOWED BY A WEEK OF REST EVERY 28 DAYS IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER (MBC). JOURNAL OF CLINICAL ONCOLOGY
Ponencia2005 DOCETAXEL FOLLOWED BY CAPECITABINE AS FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST CANCER PATIENTS: PRELIMINARY RESULTS JOURNAL OF CLINICAL ONCOLOGY
Revisión2004 Tratamiento quimioterápico adyuvante y neoadyuvante del cáncer de mama Ciencia Ginecologika
Artículo2004 TRATAMIENTO QUIMIOTERÁPICO ADYUVANTE Y NEOADYUVANTE DEL CÁNCER DE MAMA Ciencia Ginecologika
Letter2001 Comment: Fluorouracil-induced aphasia: Neurotoxicity versus cerebral ischemia [4] (multiple letters) ANNALS OF PHARMACOTHERAPY
Artículo2001 Degeneración cerebelosa paraneoplásica y carcinoma de ovario Oncología
Letter2000 Fluorouracil-induced aphasia [1] ANNALS OF PHARMACOTHERAPY
Artículo1995 Carcinoma de cervix de células vidriadas Neoplasia (Spanish Edition)
Artículo1993 Metástasis a la glándula tiroides Oncología
Artículo1993 Neuroblastoma in the adult: Three cases Neoplasia (Spanish Edition)
Artículo1993 Tumor de Merkel: revisión de la literatura a propósito de 3 casos Neoplasia (Spanish Edition)
Letter1992 Un caso de seis neoplasias diferentes REVISTA CLINICA ESPANOLA

Proyectos de Investigación

Fecha de inicio Fecha de fin Rol Denominación Agencia financiadora
01/01/2014 31/12/2016 Investigador/a Marcadores de cáncer stem cells en carcinoma microcítico de pulmón: valoración pronóstica y uso como dianas específicas para el desarrollo de terapias avanzadas mediante nanotransportadores dirigidos (PI-0051-2013) Consejería de Salud y Bienestar Social (Fundación Progreso y Salud) (Autonómico)
El investigador no tiene ningún resultado de investigación asociado